By RWJ/BARNABAS HEALTH
June 1, 2021 at 12:18 PM
Barry H. Ostrowsky, president and CEO, RWJBarnabas Health and Trina Parks, senior vice president and Corporate Chief Diversity and Inclusion Officer, RWJBarnabas Health.
Barry H. Ostrowsky, president and CEO, RWJBarnabas Health and Trina Parks, senior vice president .
Credits: RWJBarnabas Health
June 1, 2021 at 12:18 PM
WEST ORANGE, NJ – RWJBarnabas Health has joined the growing coalition pledging to advance diversity and inclusion in the workplace.
One of nearly 2,000 CEOs who have come together for CEO Action for Diversity & Inclusion™, Barry H. Ostrowsky, president and CEO is committing himself and RWJBarnabas Health to advance diversity and inclusion in the workplace.
Rutgers University
Treatment Uses Protein found in Oral Bacterium
A company founded by Rutgers School of Dental Medicine researcher Scott Kachlany received U.S. Food and Drug Administration (FDA) approval to begin a phase I clinical trial to treat cancer patients with a therapy based on Kachlany’s discovery that a protein produced by an oral bacterium can kill leukemia and lymphoma cells.
The approval clears the way for Kachlany’s company, Actinobac Biomed, to begin the trial in patients who have relapsed or refractory leukemia or lymphoma. Their experimental drug, Leukothera, has additionally proven effective in treating autoimmune diseases in animals, and Actinobac is also developing its use for that purpose.
Reply
William Zamboni, PharmD, PhD
Sha Chang, PhD
New Brunswick, N.J., May 26, 2021 – In the world of cancer therapies, nanoparticles hold great promise for delivering more effective and safer cancer treatment than the standard small molecule drugs that are commonly used today.
William Zamboni, PharmD, PhD, an expert in the pharmacology of nanoparticles at the University of North Carolina Eshelman School of Pharmacy, Sha Chang, PhD, director of medical physics research at UNC, and Rutgers Cancer Institute of New Jersey Director Steven K. Libutti, MD, FACS, whose work involves understanding the tumor microenvironment, are hoping to fight pancreatic cancer using the combination of a novel type of radiation and nanoparticles. The work is supported by a $2,792,913 grant (1R01CA247652-01A1) from the National Institutes of Health s National Cancer Institute.
Share this article
Share this article
NEW BRUNSWICK, N.J., May 19, 2021 /PRNewswire/ Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8. A total of 16 presentations including 13 abstracts, two educational sessions and one clinical science symposium have been accepted, highlighting data in numerous types of cancer, including leukemia, lymphoma, melanoma and breast, lung and kidney cancer.
E-Mail
IMAGE: HPV infection causes cells to undergo changes. If not treated these cells can, over time, become cancer cells. view more
Credit: National Cancer Institute
Today, doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation s health care systems, physicians, parents and children, and young adults to get the human papillomavirus (HPV) vaccination back on track.
Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic have caused a significant vaccination gap and lag in vital preventive services among U.S. children and adolescents especially for the HPV vaccine. The pandemic also has exacerbated health disparities, leaving Black, Indigenous and other people of color; rural; and sexual minority adolescents at even greater risk for missed doses of this cancer prevention vaccine.